Saturday, February 2, 2019

Aevi Genomic Medicine (GNMX) Stock Price Up 15%

Aevi Genomic Medicine Inc (NASDAQ:GNMX) rose 15% during trading on Friday . The stock traded as high as $0.26 and last traded at $0.23. Approximately 6,077,987 shares changed hands during mid-day trading, an increase of 41% from the average daily volume of 4,315,754 shares. The stock had previously closed at $0.20.

GNMX has been the subject of several research reports. JMP Securities cut Aevi Genomic Medicine from an “outperform” rating to a “market perform” rating in a research note on Thursday, January 3rd. ValuEngine cut Aevi Genomic Medicine from a “hold” rating to a “sell” rating in a research note on Thursday, December 20th.

Get Aevi Genomic Medicine alerts:

The company has a market cap of $12.95 million, a P/E ratio of -0.27 and a beta of 1.07.

Aevi Genomic Medicine (NASDAQ:GNMX) last released its earnings results on Thursday, November 1st. The biotechnology company reported ($0.12) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.03. As a group, analysts predict that Aevi Genomic Medicine Inc will post -0.55 EPS for the current fiscal year.

A hedge fund recently bought a new stake in Aevi Genomic Medicine stock. Bridgeway Capital Management Inc. bought a new stake in Aevi Genomic Medicine Inc (NASDAQ:GNMX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 223,500 shares of the biotechnology company’s stock, valued at approximately $275,000. Bridgeway Capital Management Inc. owned 0.35% of Aevi Genomic Medicine as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 19.63% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Aevi Genomic Medicine (GNMX) Stock Price Up 15%” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at

About Aevi Genomic Medicine (NASDAQ:GNMX)

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.

Featured Article: What is the NASDAQ?

No comments:

Post a Comment